Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis - 07/09/15
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 11 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and objective |
A systematic review was conducted to evaluate whether or not antiviral therapy with nucleotide/nucleoside analogs (NA) have survival benefit for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative treatment.
Methods |
An electronic search of PubMed, EMBASE, and the Cochrane Library was performed to identify comparative studies in which the adjuvant effects of NA for patients with HBV-related HCC after curative treatment were evaluated. Primary outcome included survival rate, and secondary outcomes included tumor recurrence rate and side effects. Review Manager 5.1.6 software was used for meta-analysis.
Results |
Twelve studies involving 6682 patients were included in our review. Meta-analysis results demonstrated that significant differences favoring the antiviral treatment groups were observed in 1-year survival rate (RR: 0.65, 95% CI: 0.53–0.79, P<0.0001), 3-year survival rate (RR: 0.58, 95% CI: 0.46–0.74, P<0.0001), and 5-year survival rate (RR: 0.56, 95% CI: 0.43–0.74, P<0.0001) compared with the control group. After NA was administered, recurrence was significantly reduced after one year (RR: 0.77, 95% CI: 0.64–0.93, P=0.006) and three years (RR: 0.81, 95% CI: 0.71–0.93, P=0.002) but not after five years (RR: 0.94, 95% CI: 0.76–1.16, P=0.55) compared with non-NA therapy.
Conclusion |
Current evidence showed that antiviral therapy with NA could improve survival and reduce early recurrence for patients with HBV-related HCC after curative treatment. More high-quality prospective trials are expected.
Le texte complet de cet article est disponible en PDF.Plan
Vol 39 - N° 4
P. 458-468 - septembre 2015 Retour au numéro
Article précédent
- Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience
- Hongyu Li, Bo Li, Yonggang Wei, Lvnan Yan, Tianfu Wen, Wentao Wang, Jiayin Yang, Wusheng Lu, Mingqing Xu
- Immature platelet fraction values predict recovery of platelet counts following liver transplantation
- Weilin Mao, Ying Hu, Yufeng Lou, Jiufeng Dou, Lingli Zou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?